ArticleFrontiers in oncology2025
Application of IVIM in the assessment of the spleen in patients with myelofibrosis.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: The purpose of this study is to investigate whether IVIM-derived spleen parameters including the true diffusion coefficient (D) and perfusion fraction (f) can serve as non-invasive biomarkers to predict fibrotic transformation of the bone marrow. Methods: Eighteen patients with MPN and 18 healthy controls (HC) underwent abdominal IVIM diffusion-weighted imaging using 1.5 T MR unit. The values of spleen parameters of D and f were compared between patients with various forms of MPN, including 8 patients with myelofibrosis (MF), 10 patients without myelofibrosis (non-MF) and (HC). A Bayesian approach was adopted in the analysis, to assess whether the D and f coefficients, along with the spleen volume, can predict disease occurrence. Results: Comparing MF patients to HC, Bayesian analysis provided strong evidence for a difference in the f parameter (BF = 18.38), while the difference between MF and non-MF patients was weaker (BF = 1.42). There was no statistically significant difference between non-MF and HC (BF = 0. 64). There was no correlation between f parameter and spleen volume (CI= -0,43; 0,38). Logistic regression analysis with logkit function confirmed that f parameter was significant predictor of MF. Conclusions: The study demonstrates that IVIM measurements of spleen perfusion in both healthy individuals and MPN patients offer valuable predictive information regarding disease development and progression. The f parameter shows promise for predicting fibrotic transformation of the bone marrow in MPN patients regardless of the size of the spleen.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.